- Home
- CLNN vs TENX Comparison
CLNN vs TENX Comparison
Compare CLNN & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLNN
- TENX
- Stock Information
- Founded
- CLNN 2012
- TENX 1967
- Country
- CLNN United States
- TENX United States
- Employees
- CLNN N/A
- TENX N/A
- Industry
- CLNN Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- CLNN Health Care
- TENX Health Care
- Exchange
- CLNN Nasdaq
- TENX Nasdaq
- Market Cap
- CLNN 23.1M
- TENX 21.6M
- IPO Year
- CLNN N/A
- TENX N/A
- Fundamental
- Price
- CLNN $3.76
- TENX $5.95
- Analyst Decision
- CLNN Strong Buy
- TENX Strong Buy
- Analyst Count
- CLNN 5
- TENX 3
- Target Price
- CLNN $40.00
- TENX $16.00
- AVG Volume (30 Days)
- CLNN 141.3K
- TENX 44.3K
- Earning Date
- CLNN 08-06-2025
- TENX 08-12-2025
- Dividend Yield
- CLNN N/A
- TENX N/A
- EPS Growth
- CLNN N/A
- TENX N/A
- EPS
- CLNN N/A
- TENX N/A
- Revenue
- CLNN $350,000.00
- TENX N/A
- Revenue This Year
- CLNN N/A
- TENX N/A
- Revenue Next Year
- CLNN $1,753.57
- TENX N/A
- P/E Ratio
- CLNN N/A
- TENX N/A
- Revenue Growth
- CLNN N/A
- TENX N/A
- 52 Week Low
- CLNN $2.28
- TENX $2.80
- 52 Week High
- CLNN $7.59
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- CLNN 52.37
- TENX 51.83
- Support Level
- CLNN $4.12
- TENX $5.62
- Resistance Level
- CLNN $4.40
- TENX $6.35
- Average True Range (ATR)
- CLNN 0.26
- TENX 0.46
- MACD
- CLNN -0.06
- TENX 0.01
- Stochastic Oscillator
- CLNN 7.89
- TENX 41.49
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.